MRNA
Moderna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$222.76
+4.01%Aug 6, 2026, 11:00 UTC
Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.
Source:Aug 4, 2026, 15:00 UTC
Moderna Inc. has started a Phase 1 clinical trial of an experimental Ebola vaccine targeting the strain causing the outbreak in the Democratic Republic of Congo.
Source:Aug 4, 2026, 15:00 UTC
Moderna announced the initiation of a Phase 1 clinical trial for its investigational mRNA vaccine mRNA-1469 against Bundibugyo ebolavirus, with first participants vaccinated in Canada.
Jul 31, 2026, 11:00 UTC
Moderna reported second quarter 2026 financial results with revenue of $0.1 billion, a GAAP net loss of $0.8 billion, and GAAP EPS of -$1.97.
Jul 31, 2026, 11:00 UTC
Moderna announced that its norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis and the company is preparing to enroll an additional cohort.
Source:Jul 16, 2026, 11:30 UTC
Arbutus Biopharma received a first payment from a settlement agreement with Moderna.
Source:Jul 9, 2026, 13:15 UTC
Moderna opens a new innovation centre in Harwell with a £1 billion UK R&D investment commitment over the next 10 years.
Source:Jul 9, 2026, 11:17 UTC
Moderna secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Source:Jul 8, 2026, 00:00 UTC
Michael McDonnell was appointed as a Class II director of Moderna, Inc. and a member of its Audit Committee, effective July 8, 2026.
Jun 29, 2026, 07:25 UTC
The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that Moderna's mFLUSIVA (mRNA-1010) has a favorable benefit-risk profile for adults aged 50 and older.
Source:Jun 25, 2026, 18:31 UTC
The FDA advisory committee recommended Moderna's flu vaccine for approval.
Source:Jun 18, 2026, 20:00 UTC
The FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of the benefit-risk profile of Moderna's investigational seasonal influenza vaccine mRNA-1010.
Jun 17, 2026, 06:38 UTC
Moderna expressed interest in investing in production facilities in Germany, potentially acquiring plants that BioNTech plans to close.
Source:Jun 16, 2026, 12:37 UTC
Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises.
Source:Jun 2, 2026, 20:34 UTC
Moderna launched Moderna Direct, an eCommerce platform powered by FFF Enterprises, to provide an enhanced ordering experience for its customers.
Source:Jun 1, 2026, 20:58 UTC
CEPI committed up to $50 million to Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based Bundibugyo ebolavirus vaccine candidate.
Source:Jun 1, 2026, 16:39 UTC
Moderna expanded its partnership with CEPI.
← PreviousPage 2